Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017 (2017), Article ID 9829436, 7 pages
https://doi.org/10.1155/2017/9829436
Research Article

Serum Cytokine Levels and Their Relation to Clinical Features in Patients with Autoimmune Liver Diseases

1Kazan State Medical University, Kazan, Russia
2Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia

Correspondence should be addressed to Diana Abdulganieva; ur.liam@s_anaid

Received 22 November 2016; Accepted 1 February 2017; Published 19 February 2017

Academic Editor: Sergey Morzunov

Copyright © 2017 Dilyara Akberova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Liberal and C. R. Grant, “Cirrhosis and autoimmune liver disease: current understanding,” World Journal of Hepatology, vol. 8, no. 28, pp. 1157–1168, 2016. View at Publisher · View at Google Scholar
  2. C. Bunchorntavakul and K. R. Reddy, “Diagnosis and management of overlap syndromes,” Clinics in Liver Disease, vol. 19, no. 1, pp. 81–97, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Jepsen, L. Grønbæk, and H. Vilstrup, “Worldwide incidence of autoimmune liver disease,” Digestive Diseases, vol. 33, supplement 2, pp. 2–12, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. J. J. Feld and E. J. Heathcote, “Epidemiology of autoimmune liver disease,” Journal of Gastroenterology and Hepatology (Australia), vol. 18, no. 10, pp. 1118–1128, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. M. S. Longhi, Y. Ma, G. Mieli-Vergani, and D. Vergani, “Adaptive immunity in autoimmune hepatitis,” Digestive Diseases, vol. 28, no. 1, pp. 63–69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. A. J. Montano-Loza and A. J. Czaja, “Cell mediators of autoimmune hepatitis and their therapeutic implications,” Digestive Diseases and Sciences, vol. 60, no. 6, pp. 1528–1542, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. L. Baier and J. Mattner, “Mechanisms of autoimmune liver disease,” Discovery Medicine, vol. 18, no. 100, pp. 255–263, 2014. View at Google Scholar · View at Scopus
  8. P. J. Trivedi and G. M. Hirschfield, “Treatment of autoimmune liver disease: current and future therapeutic options,” Therapeutic Advances in Chronic Disease, vol. 4, no. 3, pp. 119–141, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. European Association for the Study of the Liver, “EASL Clinical Practice Guidelines: management of cholestatic liver diseases,” Journal of Hepatology, vol. 51, no. 2, pp. 237–267, 2009. View at Google Scholar
  10. M. P. Manns, A. J. Czaja, J. D. Gorham et al., “Diagnosis and management of autoimmune hepatitis,” Hepatology, vol. 51, no. 6, pp. 2193–2213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. K. M. Boberg, R. W. Chapman, G. M. Hirschfield, A. W. Lohse, M. P. Manns, and E. Schrumpf, “Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue,” Journal of Hepatology, vol. 54, no. 2, pp. 374–385, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Barak, C. Selmi, M. Schlesinger et al., “Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis,” Journal of Autoimmunity, vol. 33, no. 3-4, pp. 178–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Bo, U. Broome, M. Remberger, and S. Sumitran-Holgersson, “Tumour necrosis factor α impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis,” Gut, vol. 49, no. 1, pp. 131–141, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Zhao, Y. Tang, Z. You et al., “Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression,” PLoS ONE, vol. 6, no. 4, Article ID e18909, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Maggiore, F. D. Benedetti, M. Massa, P. Pignatti, and A. Martini, “Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-α in children with autoimmune hepatitis,” Journal of Pediatric Gastroenterology and Nutrition, vol. 20, no. 1, pp. 23–27, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Dirchwolf, A. Podhorzer, M. Marino et al., “Immune dysfunction in cirrhosis: distinct cytokines phenotypes according to cirrhosis severity,” Cytokine, vol. 77, pp. 14–25, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. H. W. Zimmermann, S. Seidler, N. Gassler et al., “Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis,” PLoS ONE, vol. 6, no. 6, Article ID e21381, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Bertolani, P. Sancho-Bru, P. Failli et al., “Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells,” American Journal of Pathology, vol. 169, no. 6, pp. 2042–2053, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Al-Chalabi, B. C. Portmann, W. Bernal, I. G. McFarlane, and M. A. Heneghan, “Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival,” Alimentary Pharmacology and Therapeutics, vol. 28, no. 2, pp. 209–220, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Ding, F. Cicuttini, J. Li, and G. Jones, “Targeting IL-6 in the treatment of inflammatory and autoimmune diseases,” Expert Opinion on Investigational Drugs, vol. 18, no. 10, pp. 1457–1466, 2009. View at Publisher · View at Google Scholar · View at Scopus